RecruitingPhase 3NCT07736911

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy: A Randomized Controlled Trial.

Sponsor

Fu Jen Catholic University Hospital

Enrollment

140 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

GLP - 1

Summary

This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria8

Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week).
Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose.
Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication.
Age between 18 and 70 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Provision of written informed consent.
Outpatient status.
If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD.

Exclusion Criteria8

Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis).
History of prior upper gastrointestinal resection (stomach, intestine, or esophagus).
Any other condition deemed inappropriate by the treating physician.
Body mass index (BMI) > 40 kg/m².
Liver cirrhosis.
Parkinson's disease.
Dementia.
Use of tricyclic antidepressants or opioid medications for more than 3 months.